Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan Based Therapy in Children With Rhabdomyosarcoma
NCT06023641Phase 2Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2024
- Primary completion
- Oct 2034
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nanoliposomal irinotecan in rhabdomyosarcoma (RMS) (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose at 4 years, Event-Free Survival at 3 years and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
nanoliposomal irinotecan
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT06023641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023641.